PAIP1 (poly(A) binding protein interacting protein 1) is a translation initiation coactivator that functions primarily as a stimulator of protein synthesis. As a translation initiation factor, PAIP1 interacts with poly(A)-binding proteins to enhance translational efficiency, particularly of specific mRNA transcripts 1. The protein can be targeted by mechanisms that inhibit translation: K29 polyubiquitination of PAIP1 at lysine 179 blocks its interaction with eIF4A, thereby reducing translation of proinflammatory cytokines like IL-6 1. PAIP1 also plays a critical role in viral pathogenesis—both SARS-CoV and SARS-CoV-2 utilize their SARS-unique domains to interact with human PAIP1, enhancing selective translation of viral proteins while sparing host protein synthesis 2. Loss of PAIP1 causes reduced global protein translation, triggering integrated stress response (ISR) activation via eIF2α phosphorylation and leading to apoptotic cell death 3. Clinically, PAIP1 is frequently overexpressed in multiple cancer types including breast cancer, oral squamous cell carcinoma, liver cancer, and pancreatic cancer, where elevated expression correlates with advanced stage, metastasis, poor prognosis, and serves as an independent prognostic factor 456. Additionally, PAIP1 dysregulation contributes to myelodysplastic syndrome progression to acute myeloid leukemia by promoting aberrant translation of specific mRNA subsets 7.